U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from MedGen

Items: 1 to 20 of 111

1.
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
Penella J. Woll, Piers Gaunt, Charlotte Gaskell, Robin Young, Charlotte Benson, Ian R. Judson, Beatrice M. Seddon, Maria Marples, Nasim Ali, Sandra J. Strauss, Alexander Lee, Ana Hughes, Baljit Kaur, David Hughes, Lucinda Billingham
Br J Cancer. 2023 Oct 26; 129(9): 1490–1499. Published online 2023 Sep 8. doi: 10.1038/s41416-023-02416-6
PMCID:
PMC10628187
ArticlePubReaderPDF–1.1MCite
2.
Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial
Yongwoo David Seo, Hailing Lu, Graeme Black, Kimberly Smythe, Yuexin Yu, Cynthia Hsu, Juliana Ng, Pedro Hermida de Viveiros, E. Houston Warren, Brett A. Schroeder, Ryan B. O’Malley, Lee D. Cranmer, Elizabeth T. Loggers, Michael J. Wagner, Lynn Bonham, Venu G. Pillarisetty, Gabrielle Kane, Peter Berglund, Frank J. Hsu, Xinlei Mi, Borislav A. Alexiev, Robert H. Pierce, Stanley R. Riddell, Robin L. Jones, Jan ter Meulen, Edward Y. Kim, Seth M. Pollack
JAMA Oncol. 2023 Oct 12 : e234015. doi: 10.1001/jamaoncol.2023.4015 [Epub ahead of print]
PMCID:
PMC10570919
AbstractArticleCite
3.
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
Patrick Schöffski, Rastislav Bahleda, Andrew J. Wagner, Melissa A. Burgess, Niels Junker, Michael Chisamore, Patrick Peterson, Anna M. Szpurka, Matteo Ceccarelli, William D. Tap
Clin Cancer Res. 2023 Sep 1; 29(17): 3320–3328. Published online 2023 Jun 29. doi: 10.1158/1078-0432.CCR-23-0742
PMCID:
PMC10472093
ArticlePubReaderPDF–1008KCite
4.
Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
Giuseppe Corona, Emanuela Di Gregorio, Angela Buonadonna, Davide Lombardi, Simona Scalone, Agostino Steffan, Gianmaria Miolo
Front Pharmacol. 2023; 14: 1212634. Published online 2023 Aug 11. doi: 10.3389/fphar.2023.1212634
PMCID:
PMC10450632
ArticlePubReaderPDF–2.1MCite
5.
The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
Zhiyong Liu, Xin Wang, Jiaqiang Wang, Peng Zhang, Chao Li, Bangmin Wang, Songtao Gao, Oufei Liu, Weitao Yao
Front Oncol. 2023; 13: 1124517. Published online 2023 Feb 22. doi: 10.3389/fonc.2023.1124517
PMCID:
PMC9992731
ArticlePubReaderPDF–864KCite
6.
Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
Jiayong Liu, Tian Gao, Zhichao Tan, Shu Li, Jie Xu, Chujie Bai, Ruifeng Xue, Lu Xie, Lu Zhang, Zhengfu Fan, Wei Guo
Clin Cancer Res. 2022 Aug 15; 28(16): 3473–3479. Published online 2022 Jun 8. doi: 10.1158/1078-0432.CCR-22-0871
PMCID:
PMC9662895
ArticlePubReaderPDF–492KCite
7.
Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?
Tomoki Nakamura, Tomohito Hagi, Kunihiro Asanuma, Akihiro Sudo
Cancers (Basel) 2022 Nov; 14(21): 5214. Published online 2022 Oct 24. doi: 10.3390/cancers14215214
PMCID:
PMC9655955
ArticlePubReaderPDF–1.3MCite
8.
Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
Xin Sun, Jie Xu, Lu Xie, Wei Guo
Int J Gen Med. 2022; 15: 7581–7591. Published online 2022 Sep 28. doi: 10.2147/IJGM.S379269
PMCID:
PMC9527032
ArticlePubReaderPDF–2.8MCite
9.
Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
Marie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, Sixtine de Percin, David Balakirouchenane, Nihel Khoudour, Camille Tlemsani, Jonathan Chauvin, Audrey Thomas-Schoemann, François Goldwasser, Benoit Blanchet, Jérôme Alexandre
Pharmaceutics. 2022 Jun; 14(6): 1224. Published online 2022 Jun 9. doi: 10.3390/pharmaceutics14061224
PMCID:
PMC9231369
ArticlePubReaderPDF–1.2MCite
10.
The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
Ren‐Shu Zhang, Jie Liu, Yao‐Tiao Deng, Xin Wu, Yu Jiang
Cancer Med. 2022 Jun; 11(11): 2271–2283. Published online 2022 Feb 22. doi: 10.1002/cam4.4613
PMCID:
PMC9160813
ArticlePubReaderPDF–817KCite
11.
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
Jin Yuan, Xiaoyang Li, Shengji Yu
Cancer Control. 2021 Jan-Dec; 28: 10732748211038424. Published online 2021 Nov 29. doi: 10.1177/10732748211038424
PMCID:
PMC8727831
ArticlePubReaderPDF–721KCite
12.
Impact of Metastasectomy and Aggressive Local Therapy in Newly Diagnosed Metastatic Soft Tissue Sarcoma: An Analysis of the NCDB
Mustafa Abugideiri, James Janopaul-Naylor, Jeffrey Switchenko, Sibo Tian, William Read, Robert Press, Shervin Oskouei, Nickolas Reimer, Matthew Ferris, Richard J. Cassidy, Madhusmita Behera, David Monson, Jerome Landry, Karen D. Godette, Pretesh R. Patel
Ann Surg Oncol. Author manuscript; available in PMC 2022 Jan 1.
Published in final edited form as: Ann Surg Oncol. 2022 Jan; 29(1): 649–659. Published online 2021 Jul 16. doi: 10.1245/s10434-021-10466-4
PMCID:
PMC8688266
ArticlePubReaderPDF–422KCite
13.
Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
Laura Molenaar-Kuijsten, Milan van Meekeren, Remy B. Verheijen, Judith V. M. G. Bovée, Marta Fiocco, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Aisha B. Miah, Hans Gelderblom, Rick L. M. Haas, Neeltje Steeghs
Cancers (Basel) 2021 Nov; 13(22): 5780. Published online 2021 Nov 18. doi: 10.3390/cancers13225780
PMCID:
PMC8616484
ArticlePubReaderPDF–1.1MCite
14.
Pazopanib in rare histologies of metastatic soft tissue sarcoma
Babita Kataria, Aparna Sharma, Bivas Biswas, Sameer Bakhshi, Deepam Pushpam
Ecancermedicalscience. 2021; 15: 1281. Published online 2021 Sep 2. doi: 10.3332/ecancer.2021.1281
PMCID:
PMC8580588
ArticlePubReaderPDF–450KCite
15.
Impact of sarcopenia in advanced and metastatic soft tissue sarcoma
Dennis Strassmann, Bennet Hensen, Viktor Grünwald, Katharina Stange, Hendrik Eggers, Florian Länger, Mohamed Omar, Patrick Zardo, Hans Christiansen, Christoph W. Reuter, Frank K. Wacker, Arnold Ganser, Philipp Ivanyi
Int J Clin Oncol. 2021; 26(11): 2151–2160. Published online 2021 Jul 27. doi: 10.1007/s10147-021-01997-7
PMCID:
PMC8520878
ArticlePubReaderPDF–781KCite
16.
Radiation Therapy in Metastatic Soft Tissue Sarcoma: From Palliation to Ablation
Nishant K. Shah, Nikhil Yegya-Raman, Joshua A. Jones, Jacob E. Shabason
Cancers (Basel) 2021 Oct; 13(19): 4775. Published online 2021 Sep 24. doi: 10.3390/cancers13194775
PMCID:
PMC8508247
ArticlePubReaderPDF–255KCite
17.
A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma
Daniel Y. Reuben
J Med Cases. 2021 Apr; 12(4): 160–163. Published online 2021 Feb 8. doi: 10.14740/jmc3655
PMCID:
PMC8383654
ArticlePubReaderPDF–2.0MCite
18.
Extra nodal Rosai Dorfman disease masquerading as metastatic soft tissue sarcoma- A case report
Sanjay Bhalchandra Londhe, Kshitij Chandrakant Joshi, Puja Iyengar Ambrish
J Clin Orthop Trauma. 2021 Sep; 20: 101500. Published online 2021 Jul 8. doi: 10.1016/j.jcot.2021.101500
Correction in:
J Clin Orthop Trauma. 2021 Sep; 20: 101540.
PMCID:
PMC8319515
ArticlePubReaderPDF–2.0MCite
19.
Interim analysis of the Phase II Study: Non-Inferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft Tissue Sarcoma
Brian A. Van Tine, Angela C. Hirbe, Peter Oppelt, Ashley E. Frith, Richa Rathore, Joshua D. Mitchell, Fei Wan, Shellie Berry, Michele Landeau, George A. Heberton, John Gorcsan, III, Peter R. Huntjens, Yoku Soyama, Justin M. Vader, Jose A. Alvarez-Cardona, Kathleen W. Zhang, Daniel J. Lenihan, Ronald J. Krone
Clin Cancer Res. Author manuscript; available in PMC 2022 Jan 15.
Published in final edited form as: Clin Cancer Res. 2021 Jul 15; 27(14): 3854–3860. Published online 2021 Mar 25. doi: 10.1158/1078-0432.CCR-20-4621
PMCID:
PMC8282681
ArticlePubReaderPDF–700KCite
20.
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D Tap, Zsuzsanna Papai, Brian A Van Tine, Steven Attia, Kristen N Ganjoo, Robin L Jones, Scott Schuetze, Damon Reed, Sant P Chawla, Richard F Riedel, Anders Krarup-Hansen, Maud Toulmonde, Isabelle Ray-Coquard, Peter Hohenberger, Giovanni Grignani, Lee D Cranmer, Scott Okuno, Mark Agulnik, William Read, Christopher W Ryan, Thierry Alcindor, Xavier F Garcia del Muro, G Thomas Budd, Hussein Tawbi, Tillman Pearce, Stew Kroll, Denise K Reinke, Patrick Schöffski
Lancet Oncol. Author manuscript; available in PMC 2020 Dec 29.
Published in final edited form as: Lancet Oncol. 2017 Aug; 18(8): 1089–1103. Published online 2017 Jun 23. doi: 10.1016/S1470-2045(17)30381-9
Correction in:
volume 19 on page e78
PMCID:
PMC7771354
ArticlePubReaderPDF–1.0MCite

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center